The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib/randomized phase II study combining hepatic percutaneous perfusion with ipilimumab plus nivolumab in advanced uveal melanoma: The CHOPIN trial.
 
Thaïs M.L. Tong
No Relationships to Disclose
 
Mark C. Burgmans
Research Funding - Medtronic
 
Monique Van der Kooij
No Relationships to Disclose
 
Frank M. Speetjens
No Relationships to Disclose
 
Arian R. van Erkel
No Relationships to Disclose
 
Rutger W. van der Meer
No Relationships to Disclose
 
Shelley van den Bosch
No Relationships to Disclose
 
Mare A. Jonker
No Relationships to Disclose
 
Inge C.F.M. Roozen
No Relationships to Disclose
 
Jacob Lutjeboer
No Relationships to Disclose
 
Fenna Rijksen
Employment - Medtronic
 
Els L. van Persijn-van Meerten
No Relationships to Disclose
 
Chris H. Martini
No Relationships to Disclose
 
Remco W.M. Zoethout
Consulting or Advisory Role - Delcath Systems
 
Fred G.J. Tijl
No Relationships to Disclose
 
Christian U. Blank
Stock and Other Ownership Interests - Immagene; Uniti Cars
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures
Research Funding - Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Ellen Kapiteijn
No Relationships to Disclose